Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CLEVELAND, Feb. 01, 2016 -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 18th annual BIO CEO & Investor Conference to be held on February 8-9, 2016 in New York, NY, at The Waldorf Astoria New York.
Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Monday, February 8, 2016 at 2:00 p.m. EST in the Louis XVI Room.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies. Because its mission is to support industry-wide success, BIO presents a broad and unbiased view of investment opportunities and provides an annual forum for institutional investors, industry analysts, and senior biotechnology executives to shape the future investment landscape of the industry.
To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 90 days after the initial presentation.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
